The application of extensive proteomics revealed a panel of six biomarkers (ICAM2, FABP4, FASLG, IGFBP-2, SELE, and TNFSF13B/BAFF) that effectively distinguished (AUC ROC > 0.8) patients with LN and active renal disease (AR) from those with inactive disease (iSLE), with the majority also showing a strong correlation with clinical disease activity [55]. Here, TNFSF13B is linked to lobular neoplasia.